drugset / Trial / NCT06315491
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.
Timeline
- Start
- 2024-09-25
- Primary completion
- 2025-10
- Completion
- 2025-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CBX-12 | Other / unclassified | 100 mg/m2 | Intravenous |
| Subject | CBX-12 | Other / unclassified | 125 mg/m2 | Intravenous |